In this review, we focus on describing the emerging evidence for GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9 as candidate biomarkers across renal and bladder cancers—highlighting their biological rationales, analytical performance characteristics, and prospective roles in clinical practice. This evidence concerns the gene HMGB1 and urinary bladder carcinoma.